project id: TCGA-PRAD; case submitter id: TCGA-EJ-A65B; analyte type: DNA; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.82; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.1; rna integrity number: 8.0; age at index: 55; days to birth: -20204; ethnicity: not reported; gender: male; race: white; vital status: Alive; year of birth: 1957; age at diagnosis: 20204; ajcc clinical m: M0; ajcc clinical t: T3b; ajcc pathologic n: N0; ajcc pathologic t: T3b; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 710.0; icd 10 code: C61; last known disease status: not reported; morphology: 8255/3; primary diagnosis: Adenocarcinoma with mixed subtypes; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 5; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 359; initial weight: 300.0; sample id: d1658ea1-ddcd-4dde-a7c6-545585f2a543; sample submitter id: TCGA-EJ-A65B-01A; percent lymphocyte infiltration: 2.0; percent monocyte infiltration: 1.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent tumor cells: 45.0; percent tumor nuclei: 85.0; section location: TOP;